bDMARDs retention rate in the biosimilar era: A real-life monocentric study

References (5)

1. Smolen JS, Goncalves J, Quinn M, Benedetti F, Yongkwon JY. Era of biosimilars in rheumatology: Reshaping the healthcare environment. RMD Open 2019; 5: e000900
2. Kay J, Schoels MM, Dörner T, Emery P, Kvien TK, Smolen JS, et al. Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases. Ann Rheum Dis 2018; 77: 165-74
3. Mysler E, Pineda C, Horiuchi T, Singh E, Mahgoub E, Coindreau J, et al. Clinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatology. Rheumatol Int 2016; 36: 613-25
4. Neovius M, Arkema EV, Olsson H, Eriksson JK, Kristensen LE, Simard JF, et al. Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab. Ann Rheum Dis 2015; 74: 354- 60
5. Mok CC, Chan KY, Lee KL, Tam LS, Lee KW, Hong Kong Society of Rheumatology. Factors associated with withdrawal of the anti-TNFα biologics in the treatment of rheumatic diseases: Data from the Hong Kong Biologics Registry. Int J Rheum Dis 2014; 17 Suppl 3: 1-8.